SYNDAX PHARMACEUTICALS ($SNDX) posted quarterly earnings results for Q1 2026 on Thursday, April 30th. The company reported earnings of -$0.48 per share, beating estimates of -$0.59 by $0.11. The company also reported revenue of $64,860,000, missing estimates of $71,847,351 by $-6,987,351.
You can see Quiver Quantitative's $SNDX stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
SYNDAX PHARMACEUTICALS Insider Trading Activity
SYNDAX PHARMACEUTICALS insiders have traded $SNDX stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $SNDX stock by insiders over the last 6 months:
- MICHAEL A METZGER (Chief Executive Officer) has made 0 purchases and 2 sales selling 24,571 shares for an estimated $513,654.
- KEITH A. GOLDAN (Chief Financial Officer) has made 0 purchases and 2 sales selling 5,492 shares for an estimated $114,636.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
SYNDAX PHARMACEUTICALS Hedge Fund Activity
We have seen 108 institutional investors add shares of SYNDAX PHARMACEUTICALS stock to their portfolio, and 115 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- HOOD RIVER CAPITAL MANAGEMENT LLC added 2,316,553 shares (+inf%) to their portfolio in Q4 2025, for an estimated $48,670,778
- VANGUARD GROUP INC added 1,091,717 shares (+21.2%) to their portfolio in Q4 2025, for an estimated $22,936,974
- BANK OF AMERICA CORP /DE/ added 1,012,993 shares (+27.4%) to their portfolio in Q4 2025, for an estimated $21,282,982
- MILLENNIUM MANAGEMENT LLC removed 994,519 shares (-95.0%) from their portfolio in Q4 2025, for an estimated $20,894,844
- UBS GROUP AG removed 958,294 shares (-57.2%) from their portfolio in Q4 2025, for an estimated $20,133,756
- QUBE RESEARCH & TECHNOLOGIES LTD removed 956,707 shares (-58.2%) from their portfolio in Q4 2025, for an estimated $20,100,414
- ENSIGN PEAK ADVISORS, INC added 789,480 shares (+97.6%) to their portfolio in Q4 2025, for an estimated $16,586,974
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
SYNDAX PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $SNDX in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 12/09/2025
- Barclays issued a "Overweight" rating on 11/24/2025
To track analyst ratings and price targets for SYNDAX PHARMACEUTICALS, check out Quiver Quantitative's $SNDX forecast page.
SYNDAX PHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $SNDX recently. We have seen 10 analysts offer price targets for $SNDX in the last 6 months, with a median target of $41.5.
Here are some recent targets:
- Corinne Johnson from Goldman Sachs set a target price of $34.0 on 04/01/2026
- Salim Syed from Mizuho set a target price of $43.0 on 03/31/2026
- Faisal Khurshid from Jefferies set a target price of $40.0 on 03/30/2026
- Anupam Rama from JP Morgan set a target price of $45.0 on 03/09/2026
- Yigal Nochomovitz from Citigroup set a target price of $57.0 on 03/02/2026
- Justin Zelin from BTIG set a target price of $56.0 on 12/09/2025
- Etzer Darout from Barclays set a target price of $35.0 on 11/24/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
